HCC Second-Line Post-ICI — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMedical OncologyHCC Second-Line Post-ICIRACP Adult Medicine

A 68-year-old man with advanced HCC (BCLC C) on first-line atezolizumab/bevacizumab progresses after 8 months. Child-Pugh A. Second-line option?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Any TKI is acceptable

Post-ICI+bev progression: second-line TKIs (sorafenib, lenvatinib, cabozantinib, regorafenib). No strong evidence favouring one over another.

Reference: Cancer Council Australia – 2020; AASLD – 2023